Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 223-810-8 | CAS number: 4083-64-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- October 2012 to January 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study performed according to OECD 429 and under GLP-conditions.
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Principles of method if other than guideline:
- Not relevant
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- other: CBA/Ca
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories UK Ltd., Oxon, UK
- Age at study initiation: 8 - 12 weeks
- Weight at study initiation: 15 - 23 g
- Housing: Animals were individually housed in suspended solid-floor polypropylene cages furnished with softwood woodflakes
- Diet (e.g. ad libitum): Ad libitum (2014C Teklad Global Rodent diet supplied by Harlan Laboratories UK Ltd., Oxon, UK
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25
- Humidity (%): 30 - 70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 hours dark / 12 hours light
IN-LIFE DATES: From: 15 November 2012 To: 04 December 2012 - Vehicle:
- dimethylformamide
- Concentration:
- 10%, 25% and 50%
- No. of animals per dose:
- 5
- Details on study design:
- RANGE FINDING TESTS:
- Compound solubility: Dimethyl formamide produced the highest concentration that was suitable for dosing.
- Irritation: one mouse was treated daily with undiluted test item to the dorsal surface of each ear for three consecutive days. Local irritation was scored daily.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: Local Lymph Node Assay (LLNA) - individual animal approach
- Criteria used to consider a positive response: Stimulation Index (SI) ≥ 3
TREATMENT PREPARATION AND ADMINISTRATION:
- The mice were treated by daily application of 25µL of the appropriate concentration of the test item to the dorsal surface of each ear for three consecutive days.
- The test item was formulated within two hours of being applied to the test system. It is assumed that the formulation was stable for this duration. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- Data was processed to give group mean values for disintegrations per minute and standard deviations where appropriate. Individual and group mean disintegrations per minute values were assessed for dose reponse relationships by analysis of homogeneity of variance followed by one way analysis of variance (ANOVA). In the event of a significant result from the ANOVA, pairwise comparisons were performed between control and treated groups. For homogenous datasets Dunnett's Multiple Comparison test was used and for non-homogenous datasets Dunnett's T3 Multiple Comparison Method was used.
- Positive control results:
- SI expressed as the mean radioactive incorporation for α-Hexylcinnamaldehyde was 4.38, which is a positive result (SI ≥ 3).
- Parameter:
- SI
- Remarks on result:
- other: - 10%: 0.93 - 25%: 0.86 - 50%: 1.00
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: Mean DPM/animal (Standard Deviation) - Vehicle (0%): 2186.32 (± 939.12) - 10%: 2029.45 (± 836.32) - 25% 1890.47 (± 962.98) - 50% 2191.61 (± 670.48)
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of this study, p-Toluenesulphonamide was considered to be not sensitising. A maximum Stimulation Index of 1.00 for the highest tested dose (50%) indicates that the substance does not need to be classified as a sensitiser according to the criteria outlined in Annex I of 1272/2008/EC and Annex VI of 67/548/EEC.
- Executive summary:
This Local Lymph Node Assay (OECD 429) was performed to determine the sensitising potential of p-Toluenesulphonamide in CBA/Ca mice. Groups of 5 mice were treated with 10, 25 or 50% p-Toluenesulphonamide v/v in dimethyl formamide. α-Hexylcinnamaldehyde (85% pure), prepared as a 15% v/v dilution in dimethyl formamide, was used as positive control. Clinical observations and bodyweights were recorded and lymph node proliferation was determined using 3HTdR incorporation.
The number of radioactive disintegrations per minute (dpm) reflect the proliferation reponse of lymph node cells, and were 2186.32, 2029.45, 1890.47, and 2191.61 mean dpm/animal for the 0%, 10%, 25%, and 50% concentration groups, respectively. This corresponds with a lymph node proliferation Stimulation Index (SI) of 0.93, 0.86 and 1.00, respectively, for the p-Toluenesulphonamide-treated groups (10%, 25%, 50%). No mortality and no signs of systemic toxicity were observed. No effects on bodyweight (gain) were observed.
Under the conditions of this study, p-Toluenesulphonamide was considered to be not sensitising. A maximum Stimulation Index of 1.00 for the highest tested dose (50%) indicates that the substance does not need to be classified as a sensitiser according to the criteria outlined in Annex I of 1272/2008/EC and Annex VI of 67/548/EEC.
Reference
- Clinical observations and mortality data: no mortality was observed. No signs of systemic toxicity were noted in the test or control animals during the test.
- Bodyweight: Bodyweight changes of the test animals between Day 1 and Day 6 were comparable to those observed in the corresponding control group animals over the same period.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The result of PTSA is read across to PTSI. This is considered justified because PTSI is extremely reactive with water and reacts instantaneously into the source substance PTSA. Due to this extreme reactivity it is considered unethical to perform this study with PTSI on animals.
A Local Lymph Node Assay (OECD 429) was performed with PTSA to determine its sensitising potential in CBA/Ca mice. Groups of 5 mice were treated with 10, 25 or 50% p-Toluenesulphonamide v/v in dimethyl formamide. α-Hexylcinnamaldehyde (85% pure), prepared as a 15% v/v dilution in dimethyl formamide, was used as positive control. Clinical observations and bodyweights were recorded and lymph node proliferation was determined using 3HTdR incorporation.
A lymph node proliferation Stimulation Index (SI) of 0.93, 0.86 and 1.00 was observed for 10%, 25%, and 50% PTSA, respectively. No mortality and no signs of systemic toxicity were observed. No effects on bodyweight (gain) were observed. Under the conditions of this study, PTSA was considered to be not sensitising, as the maximum Stimulation Index of 1.00 for the highest tested dose (50%) indicates that the substance does not need to be classified as a sensitiser according to the criteria outlined in Annex I of 1272/2008/EC and Annex VI of 67/548/EEC.
Migrated from Short description of key information:
Local Lymph Node Assay (OECD429, GLP) with PTSA (max 50%): not sensitising
Justification for selection of skin sensitisation endpoint:
Reliable GLP study according to OECD 429
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
According to Annex VI of CLP, PTSI is classified for respiratory sensitisation.
Migrated from Short description of key information:
According to Annex VI of CLP, PTSI is classified for respiratory sensitisation.
Justification for classification or non-classification
Based on read across to the results of the key study with PTSA, PTSI does not need to be classified for skin sensitisation when considering the criteria outlined in Annex I of 1272/2008/EC and Annex VI of 67/548/EEC. However, based on Annex VI of 1272/2008/EC (CLP), PTSI has to be classified for respiratory sensitisation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.